1. Research article

    Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial

    Masako Utsunomiya, Hiroaki Dobashi, Toshio Odani, Kazuyoshi Saito, Naoto Yokogawa, Kenji Nagasaka, Kenchi Takenaka, Makoto Soejima, Takahiko Sugihara, Hiroyuki Hagiyama, Shinya Hirata, Kazuo Matsui, Yoshinori Nonomura, Masahiro Kondo, Fumihito Suzuki, Makoto Tomita…

    Published on: 18 January 2017

View all articles

View all articles

Aims and scope

Arthritis Research & Therapy is an international, peer-reviewed online journal, publishing original research, reviews, commentaries and reports. The major focus of the journal is on cellular and molecular mechanisms of arthritis, musculoskeletal conditions and systemic autoimmune rheumatic diseases and translation of this knowledge into advances in clinical care. Original basic, translational laboratory and clinical research is considered for publication along with results of early and late phase therapeutic trials.

Review series: New technologies

Written by renowned experts in the field, this collection of open access Review articles explores the use of RNA sequencing, cytometry, metabolomics and next-generation DNA sequencing in rheumatic disease.

Featured review: Progress in defining clinically meaningful changes for clinical trials in nonrenal manifestations of SLE disease activity

“Since 2002, one new agent has been approved by the US Food and Drug Administration for systemic lupus erythematosus (SLE). Experiences from the field conducting trials of all the agents tested during this period have provided valuable practical insights. These insights harnessed with basic methodological work on the minimal clinically important difference (MCID) should improve the efficiency and the clinical relevance of future trials.”

This review, by Choi et al., provides an update on methods to determine a clinically meaningful difference when conducting trials of new agents for SLE.